Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
Monica A Donnelley,1,2 Elizabeth S Zhu,1 George R Thompson 3rd3 1Department of Inpatient Pharmacy, University of California – Davis, Sacramento, 2Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, 3Department of Medicine, Division of Infectious Diseases, Univer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/isavuconazole-in-the-treatment-of-invasive-aspergillosis-and-mucormyco-peer-reviewed-article-IDR |
| _version_ | 1819081803448713216 |
|---|---|
| author | Donnelley MA Zhu ES Thompson GR 3rd |
| author_facet | Donnelley MA Zhu ES Thompson GR 3rd |
| author_sort | Donnelley MA |
| collection | DOAJ |
| description | Monica A Donnelley,1,2 Elizabeth S Zhu,1 George R Thompson 3rd3 1Department of Inpatient Pharmacy, University of California – Davis, Sacramento, 2Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, 3Department of Medicine, Division of Infectious Diseases, University of California – Davis, Davis, CA, USAAbstract: We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy. Keywords: isavuconazonium, antifungal, zygomycosis, mucor, mould infection, pharmacokinetics, pharmacodynamics, clinical efficacy, therapy, new agent |
| first_indexed | 2024-12-21T20:06:35Z |
| format | Article |
| id | doaj.art-5ec6659919ef47029f766cdab913bf1c |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-12-21T20:06:35Z |
| publishDate | 2016-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-5ec6659919ef47029f766cdab913bf1c2022-12-21T18:51:50ZengDove Medical PressInfection and Drug Resistance1178-69732016-06-012016Issue 1798627267Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsDonnelley MAZhu ESThompson GR 3rdMonica A Donnelley,1,2 Elizabeth S Zhu,1 George R Thompson 3rd3 1Department of Inpatient Pharmacy, University of California – Davis, Sacramento, 2Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, 3Department of Medicine, Division of Infectious Diseases, University of California – Davis, Davis, CA, USAAbstract: We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy. Keywords: isavuconazonium, antifungal, zygomycosis, mucor, mould infection, pharmacokinetics, pharmacodynamics, clinical efficacy, therapy, new agenthttps://www.dovepress.com/isavuconazole-in-the-treatment-of-invasive-aspergillosis-and-mucormyco-peer-reviewed-article-IDRIsavuconazoleantifungalaspergillosiszygomycosisisavuconazonium sulfatemucormycosis |
| spellingShingle | Donnelley MA Zhu ES Thompson GR 3rd Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections Infection and Drug Resistance Isavuconazole antifungal aspergillosis zygomycosis isavuconazonium sulfate mucormycosis |
| title | Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| title_full | Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| title_fullStr | Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| title_full_unstemmed | Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| title_short | Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| title_sort | isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections |
| topic | Isavuconazole antifungal aspergillosis zygomycosis isavuconazonium sulfate mucormycosis |
| url | https://www.dovepress.com/isavuconazole-in-the-treatment-of-invasive-aspergillosis-and-mucormyco-peer-reviewed-article-IDR |
| work_keys_str_mv | AT donnelleyma isavuconazoleinthetreatmentofinvasiveaspergillosisandmucormycosisinfections AT zhues isavuconazoleinthetreatmentofinvasiveaspergillosisandmucormycosisinfections AT thompsongr3rd isavuconazoleinthetreatmentofinvasiveaspergillosisandmucormycosisinfections |